Merck & Co. Hits Target With Pneumococcal Vaccine, As Rivalry With Pfizer Continues

The vaccine, V116, targets eight unique serotypes, and it is particularly geared toward preventing pneumococcal disease in adults, especially the elderly, according to Merck.